# Table of Contents

## Highlights of This Issue 3359

### SPECIAL FEATURES

#### CCR Translations

3361  **MET as a Target in Papillary Renal Cell Carcinoma**  
André P. Fay, Sabina Signoretti, and Toni K. Choueiri  
*See related article, p. 3411*

#### CCR Perspectives in Drug Approval

3364  **U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009**  
Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

#### Statistics in Clinical Cancer Research

3371  **Blocking and Randomization to Improve Molecular Biomarker Discovery**  
Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

#### Molecular Pathways

3379  **Molecular Pathways: CDK4 Inhibitors for Cancer Therapy**  
Mark A. Dickson

3384  **Molecular Pathways: Niches in Metastatic Dormancy**  
Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

#### Review

3390  **Infusions of Allogeneic Natural Killer Cells as Cancer Therapy**  
Wing Leung

## HUMAN CANCER BIOLOGY

3401  **Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions**  
Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

3411  **MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array**  
Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahra Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couver, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier  
*See related article, p. 3361*

3422  **Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer**  
Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Ofringa, Jens Werner, and Eduard Ryschich

3434  **Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer**  
Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

## CANCER THERAPY: PRECLINICAL

3446  **Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma**  
Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglio, Bjorn Titz, Thiliee Chodon, Thomas G. Graebner, Begonya Comin-Anduix, and Antoni Ribas
3458 Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)  

3472 Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis  
Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang

3485 Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells  
Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser

3496 Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage  
Giannaria Liccari, John A. Hartley, and Daniel Hochhauser

3507 Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT  

3515 Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity  
Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandrea T. Phan, Hong Zhao, John E. Scott, Li-An Yeh, and Stephen T.C. Wong

3521 TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance  
Laxmi Silwal-Pandit, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, Steven McKinney, Tomo Osako, David A. Quigley, Vessela N. Kristensen, Samuel Aparicio, Anne-Lise Borresen-Dale, Carlos Caldas, and Anita Langerød

CANCER THERAPY: CLINICAL

3581 A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer  
Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eysa Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton

3589 Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML  
Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Herdliehofer, Berthold Streubel, Werner Rabitsch, Wolfgang R. Sper, Matthias Mayerhofer, Thomas Külke, and Peter Valent
LETTERS TO THE EDITOR

3623  SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

3625  SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

ABOUT THE COVER

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.